Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Van Rhee, Frits

PropertyValue
overview Dr. Frits van Rhee received his medical degree at Erasmus University, Rotterdam, Netherlands, and his PhD at the Imperial College of Science, Medicine and Technology, University of London. He trained in internal medicine and hematology in the UK, and in bone marrow transplantation (BMT) at Oxford and the Royal Postgraduate Medical School in London. Dr. van Rhee is a professor of medicine and director of developmental and translational medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences. He also holds the Charles and Clydene Scharlau Chair for Hematological Malignancies Research. Dr. van Rhee holds memberships in the International Society for Experimental Hematology, the International Society for Cellular Therapy, and the European Group for Bone and Marrow Transplantation. He serves on the editorial review boards for Annals of Hematology, Bone Marrow Transplantation, and Cytotherapy. He has written hundreds of manuscripts and abstracts, as well as presented at scientific meetings. Dr. van Rhee's current research focuses on immunotherapy for myeloma. Dr. van Rhee is also a world-leading expert in Castleman's Disease.PublicationsMake an appointment with the UAMS Myeloma Institute

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item TypeName
Academic Article Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
Academic Article NY-ESO-1 immunotherapy for multiple myeloma.
Academic Article Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
Academic Article Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
Academic Article Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
Concept Immunotherapy
Concept Immunotherapy, Adoptive
Academic Article Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector.
Academic Article Allogeneic Immunotherapy for Malignant Transfusion
Academic Article Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors
Academic Article Recombinant Aspergullus fumigatus antigen 4 (Af4) induces potent type 1 cellular immune responses: implications for immunotherapy of Aspergillus infections
Academic Article Cancer and Gene Therapy
Academic Article Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Academic Article Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Academic Article The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
Academic Article Immunologic approaches for the treatment of multiple myeloma.
Grant UARK 2003-26, A Pilot Study of MAGE-3 and NY_ESO Immunotherapy in Combination with DT PACE Chemotherapy/Autologous Transplant in Agressive Mutliple My
Academic Article Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions.
Academic Article Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.
Academic Article CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.
Academic Article BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
Academic Article Perspectives on the Treatment of Multiple Myeloma.

Search Criteria
  • Immunotherapy